Novo Nordisk says Health Canada has approved its weight loss drug Wegovy to reduce the risk of heart attacks in some adults. Kyle Benning has the details and more in Health Matters for Nov. 27, 2024.
Health Matters
Health Matters: Wegovy approved to reduce heart attack risk
More Videos
-
Health Matters: Roundup safety research retracted by its publisher
-
Health Matters: Former U.S. FDA leaders condemn internal memos
-
Alberta woman prepares to welcome quadruplets
-
Health Matters: Manitoba parents say school staff should be trained to help children with type 1 diabetes
-
Cancer survivor launches a first-of-its-kind registry in Canada
-
Health Matters: Study finds more prostate cancer cases being diagnosed at stage 4
You are viewing an Accelerated Mobile Webpage.
View Original Article